A Phase IIa randomized, double-blind, placebo-controlled clinical trial comparing the efficacy and safety of ZYN001 with placebo in fibromyalgia and peripheral neuropathic pain

Trial Profile

A Phase IIa randomized, double-blind, placebo-controlled clinical trial comparing the efficacy and safety of ZYN001 with placebo in fibromyalgia and peripheral neuropathic pain

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs ZYN 001 (Primary)
  • Indications Fibromyalgia; Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017, according to a Zynerba Pharmaceuticals media release.
    • 09 May 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jul 2017,according to a Zynerba Pharmaceuticals media release.
    • 17 Oct 2016 This trial is expected to begin in the second half of 2017, according to a Zynerba Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top